Baxter International stock trades steadily as spin-off and portfolio reshaping reshape earnings prof

{
  "signal_id": "1f2274a7-cb4b-3eaa-db4a-587ae1fea52a",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-07-18T15:42:55+00:00",
  "company": {
    "name": "Baxter",
    "domain": "baxter.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/baxter-international-stock-trades-steadily-as-spin-off-and-portfolio/69797182",
    "title": "Baxter International stock trades steadily as spin-off and portfolio reshaping reshape earnings prof - ad-hoc-news.de",
    "excerpt": "Baxter International Inc. (ISIN US0673431090) stock continues to reflect the companys reshaped portfolio after the spin-off of its kidney care business and a stronger focus on margins and cash generation. As of 31 December 2023, Baxter reported a market capitalization of around $22 billion based on its New York Stock Exchange listing under the ticker BAX, anchoring the company firmly among large US medical technology and hospital-supply names. According to Baxter International Inc.s Form 10-K for the year ended 31 December 2023, the company generated total net sales of $12.97 billion in fiscal 2023. The report shows that this represented a decrease compared with the prior year, largely reflecting the impact of portfolio changes and a more selective approach to low-margin activities, but it also highlights areas of resilience such as hospital products and pharmaceuticals. Baxter divides its operations into several reporting segments, including Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. In 2023, the Medical Products and Therapies segment contributed the largest share of revenue, with several billion dollars in net sales driven by infusion systems, intravenous solutions, and critical-care products used in hospitals worldwide. The Pharmaceuticals segment, which includes injectable drugs and anesthesia products, continued to provide a...",
    "summary": "Baxter International reported an operating income of approximately $1.1 billion from continuing operations in 2023.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2699597_1920_1080.webp",
    "confidence": 0.95,
    "published_at": "2026-07-18T15:42:55Z",
    "effective_date": "2023-12-31",
    "article_sentence": "The same 2023 Form 10-K shows that Baxter reported operating income of approximately $1.1 billion from continuing operations in 2023, compared with a lower figure in 2022.",
    "amount_normalized": 1100000000
  }
}

curl https://signals.autobound.ai/v1/signals/1f2274a7-cb4b-3eaa-db4a-587ae1fea52a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"baxter.com","limit":20}'